Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service

PulmoSIM Therapeutics Announces Strategic Partnership with Top Respiratory Hospitals to Initiate Clinical Development of PT001 to Treat Pulmonary Arterial Hypertension

PulmoSIM Therapeutics (PulmoSIM), the pharmaceutical subsidiary of VeriSIM Life, Inc., is pleased to announce today that it has entered into a strategic partnership with the investigators from National Jewish Health and Brown University for the clinical development of PT001, a drug that targets multiple responsible pathways in PAH to provide curative treatment. The Food and Drug Administration (FDA) recently granted orphan drug designation for PT001 for the treatment of PAH.

"We're thrilled as we embark on our clinical trials program for PT001, and look forward to applying for the Investigational New Drug Application (IND) very soon," said Dr. Jo Varshney, DVM, PhD, CEO PulmoSIM. "PAH is a rare but fatal disease where the only cure is a lung transplant. We are leveraging VeriSIM Life's Virtual Drug Development Engine, BIOiSIM, to prioritize the development of PT001, which, unlike currently available therapeutics, has the ability to stop and reverse the progression of PAH."

PAH is a rare, progressive and life-threatening disease impacting 2-5 per million adults. It's characterized by high blood pressure in the arteries of the lungs with accompanying right heart failure. There is a critical unmet need for treatments that could delay, or reverse, the disease progression in patients.

"The great benefit of PT001 is its potential to not only ease symptoms but further halt or reverse the progression of PAH; we are excited to start this clinical-trial collaboration with our partners," said Dr. Vivek Gupta, PhD, Scientific Founder of PulmoSIM. "Current treatments for PAH do not stop the underlying drivers of the disease, hence there is an urgent need for therapies that can address the progression checkpoints."

"PAH is a chronic disease and we recognize the importance of developing a curative treatment," said Tim Lahm, MD, who is joining National Jewish Health as a Professor of Medicine and Director of Pulmonary Vascular Biology in Fall-2021. "We are excited to work with the PulmoSIM team and clinical investigator-partner from Brown University to develop PT001 further to show its clinical efficacy."

Corey E. Ventetuolo, MD, MS, an Associate Professor at Brown University, and Associate Director of the Rhode Island Hospital Pulmonary Hypertension Center, said, "I am very excited to be a part of this collaboration to accelerate the development of PT001 toward a curative treatment in the fight against this devastating disorder, which will require the integration and coordination of expertise across multiple fields of study. I'm glad to play a role in the design and execution of the clinical trials."

Stay tuned for more information on patient enrollment and trial site/s. For more information, you can reach us at: info@pulmosimtx.com.

About PulmoSIM Therapeutics: PulmoSIM Therapeutics is developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life.

These press releases may also interest you

at 20:09
Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of pediatric patients aged 10...

at 20:04
Eli Lilly and Company is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe), to the consumer/user level. Lilly is...

at 20:00
The homecare oxygen concentrators market is poised to grow by USD 1.21 billion during 2021-2025, progressing at a CAGR of about 15% during the forecast period. Download Our Free Sample Report and gain access to detailed customer landscape matrix...

at 20:00
The CDC reported that more than 93,000 people died of a drug overdose in the United States last year ? a record number that reflects a rise of nearly 30 percent from 2019. With the pandemic ongoing and the presence of fentanyl-laced drugs continuing...

at 19:39
The food recall warning issued on September 8, 2021 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. European Butcher...

at 19:00
Manifest House today announced a crowdfunding campaign to open their first physical location, a wellness-focused luxury overnight rental designed for group retreats. Founder and CEO, Angelee Andorfer-Lopez has a vision to bring the heart and soul of...

News published on 26 july 2021 at 12:50 and distributed by: